Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

PZ Cussons LFL revenues grow in FY25, sells stake in Nigerian JV

(Sharecast News) - Consumer goods company PZ Cussons said on Wednesday that like-for-like revenues were expected to have grown 8% in FY25, with reported revenues seen at roughly £505.0m. PZ Cussons said its H2 performance was driven by continued strong revenue growth in Africa, given the inflationary macroeconomic environment in Nigeria.

Elsewhere, PZ's Asia-Pacific operations also returned to growth in H2, driven by strong revenue growth in Indonesia, while revenues from Australia and New Zealand, on the other hand, declined in "a soft market", and Europe and Americas revenue was flat in FY25.

Looking forward, the FTSE 250-listed group now expects FY25 adjusted operating profits to be between £52.0m and £55.0m, down from its previous guidance of £52.0m to £58.0m.

PZ Cussons also announced that it has sold its 50% equity stake in PZ Wilmar, its Nigerian edible oils joint venture, for $64.0m after taxes, fees and other costs.

Proceeds will be used to reduce gross debt and, as a result, "materially improve" key credit and bank covenant metrics. Completion was expected to take place in the last quarter of the 2025 calendar year.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.